Cell Microenvironment Gradient Homeostasis Regulation Theory: Mechanisms of Cancer Onset and Development and a New Framework for Systematic Therapy

Traditional cancer research and treatment have long been limited by the "single-gene mutation determinism" and "local killing centralism", making it difficult to fundamentally explain core clinical problems such as recurrence, metastasis, and immunotherapy resistance. Based on the biorthogonal projection principle of the Gradient Phase Field Unified Theory, integrating research achievements in tumor microenvironment, cell biology, immuno-oncology, and clinical oncology, this study proposes the Cell Microenvironment Gradient Homeostasis Regulation Theory (CGMHR). It constructs five qualitative dimensions (homeostasis-orthogonality-drift-boundary-disturbance) and three quantitative indicators (CMGDI, Orthogonality Score OS, Drift Dispersion DD), defining cancer as a systemic homeostatic imbalance disease caused by cell microenvironment gradient disorder, which leads to the functional failure of the body's innate immune-signal coupling regulatory network and the collapse of the cell proliferation-differentiation biorthogonal balance axis. Based on the biorthogonal sum-of-squares conservation rule , the theory establishes a quantitative system, forms a implementable scoring method according to organ-specific thresholds, constructs a three-stage pathogenesis of precancerous lesions-in situ cancer-invasive metastatic cancer, and proposes a three-dimensional coordinated systematic therapy system: global microenvironment homeostasis reconstruction → local microenvironment precise suppression → coupling regulatory network function repair. Integration of recent clinical evidence shows that this theory can optimize disease-free survival in early and mid-stage cancer, improve objective response rate and survival time in advanced stage, and provide a basis for risk prevention and control in high-risk groups. This theory provides a quantifiable and implementable new framework for systematic cancer therapy.